Development of histone deacetylase inhibitors for cancer treatment (Q36788512)

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Cancer genes and the pathways they control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone acetylation in chromatin structure and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

DNA methylation patterns and epigenetic memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Gene silencing in cancer in association with promoter hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Worms gang up on bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Mammalian chromodomain proteins: their role in genome organisation and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Sirtuins in aging and age-related disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

The Sir 2 family of protein deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Diversity in the Sir2 family of protein deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitors in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Inhibitors of histone deacetylase as new anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitors: from target to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Expression profile of histone deacetylase 1 in gastric cancer tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitors: insights into mechanisms of lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Genes modulated by histone acetylation as new effectors of butyrate activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

SU5416 delays wound healing through inhibition of TGF-beta 1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Sodium valproate induces apoptosis in the rat hepatoma cell line, FaO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase interacts directly with DNA topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, a

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

The ABCs of SMC proteins: two-armed ATPases for chromosome condensation, cohesion, and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

RITS acts in cis to promote RNA interference-mediated transcriptional and post-transcriptional silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Regulation of microglial inflammatory response by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Acetylation: a regulatory modification to rival phosphorylation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

The diversity of acetylated proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Stat3 dimerization regulated by reversible acetylation of a single lysine residue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Regulation of E2F1 activity by acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Acetylation of the p53 DNA-binding domain regulates apoptosis induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Acetylation of Stat1 modulates NF-kappaB activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

A specific lysine in c-Jun is required for transcriptional repression by E1A and is acetylated by p300

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Acetylation and deacetylation of non-histone proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Effect of all-trans retinoic acid and sodium butyrate in vitro and in vivo on thyroid carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Sensitization to UV-induced apoptosis by the histone deacetylase inhibitor trichostatin A (TSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Bmf contributes to histone deacetylase inhibitor-mediated enhancing effects on apoptosis after ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Role of the histone deacetylase complex in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase is a target of valproic acid-mediated cellular differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

A common mechanism of action for three mood-stabilizing drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase activity is required for full transcriptional repression by mSin3A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

CoREST is an integral component of the CoREST- human histone deacetylase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase 1: a target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase 1 is required for cell cycle exit and differentiation in the zebrafish retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

A dynamic role for HDAC7 in MEF2-mediated muscle differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Differential localization of HDAC4 orchestrates muscle differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

HDAC6 is a microtubule-associated deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Identification of novel isoform-selective inhibitors within class I histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Cell cycle behavior of human HP1 subtypes: distinct molecular domains of HP1 are required for their centromeric localization during interphase and metaphase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583